Cover Image
市場調查報告書

美國的心律管理設備市場預測

United States Cardiac Rhythm Management Market Outlook to 2020

出版商 GlobalData 商品編碼 303987
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
Back to Top
美國的心律管理設備市場預測 United States Cardiac Rhythm Management Market Outlook to 2020
出版日期: 2014年05月16日 內容資訊: 英文 143 Pages
簡介

本報告提供美國的心律管理設備市場相關資料,提供心臟再同步化治療用設備(心臟整流去顫器及心律調節器),植入式心臟除顫器,植入式心電圖記錄計,心律調節器等各類別銷售額,銷售數的實際成果及預測,平均價格,企業佔有率,流通佔有率,再彙整主要企業簡介,開發中產品,主要的財務相關交易等最新資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 報告的內容
  • 心律管理設備市場區分
  • 該報告對象市場定義

第3章 美國的心律管理設備

  • 收益(實際成果)
  • 收益(預測)
  • 銷售數(實際成果)
  • 銷售數(預測)
  • 平均價格
  • 流通佔有率:各收益
  • 企業佔有率:各收益

第4章 主要企業概要

  • Medtronic, Inc.
  • St.Jude Medical, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Sorin S.p.A.

第5章 開發中產品

第6章 財務交易情勢

  • 收購
  • 發行公司債券
  • 股票上市
  • 聯盟
  • 創業融資

第7章 最近的趨勢

  • corporate·通訊
  • 財務發表
  • 政府及公益相關
  • 法律規章
  • 其他重要的動向
  • 產品資訊
  • 策略及產業規劃

第8章 附錄

圖表

目錄
Product Code: GDMECC0332DB

GlobalData's new report, "United States Cardiac Rhythm Management Market Outlook to 2020", provides key market data on the United States Cardiac Rhythm Management Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Cardiac Resynchronisation Therapy (Defibrillators and Pacemakers), Implantable Cardioverter Defibrillators, Implantable Loop Recorders and Pacemakers.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiac Rhythm Management Market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size for Cardiac Rhythm Management Devices categories - Cardiac Resynchronisation Therapy, Implantable Cardioverter Defibrillators, Implantable Loop Recorders and Pacemakers.
  • Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
  • 2012 company shares and distribution shares data for the market category.
  • Global corporate-level profiles of key companies operating within the United States Cardiac Rhythm Management Devices market.
  • Key players covered include Medtronic, Inc., St. Jude Medical, Inc., Boston Scientific Corporation and BIOTRONIK SE & Co. KG.

Reasons to buy

  • Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. What Is This Report About?
  • 2.2. Cardiac Rhythm Management Market Segmentation
  • 2.3. Definitions of Markets Covered in the Report

3. Cardiac Rhythm Management Market, United States

  • 3.1. Cardiac Rhythm Management Market, United States, Revenue ($m), 2005-2012
  • 3.2. Cardiac Rhythm Management Market, United States, Revenue ($m), 2012-2020
    • 3.2.1. Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2005-2012
    • 3.2.2. Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2005-2012
    • 3.2.3. Pacemakers Market, United States, Revenue ($m), by Segment, 2005-2012
    • 3.2.4. Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), by Segment, 2012-2020
    • 3.2.5. Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), by Segment, 2012-2020
    • 3.2.6. Pacemakers Market, United States, Revenue ($m), by Segment, 2012-2020
  • 3.3. Cardiac Rhythm Management Market, United States, Volume (Units), 2005-2012
  • 3.4. Cardiac Rhythm Management Market, United States, Volume (Units), 2012-2020
    • 3.4.1. Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2005-2012
    • 3.4.2. Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2005-2012
    • 3.4.3. Pacemakers Market, United States, Volume (Units), by Segment, 2005-2012
    • 3.4.4. Cardiac Resynchronisation Therapy Market, United States, Volume (Units), by Segment, 2012-2020
    • 3.4.5. Implantable Cardioverter Defibrillators Market, United States, Volume (Units), by Segment, 2012-2020
    • 3.4.6. Pacemakers Market, United States, Volume (Units), by Segment, 2012-2020
  • 3.5. Cardiac Rhythm Management Market, United States, Average Price ($), 2005-2020
  • 3.6. Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), 2011-2012
  • 3.7. Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), 2011-2012

4. Overview of Key Companies in United States, Cardiac Rhythm Management Market

  • 4.1. Medtronic, Inc.
    • 4.1.1. Company Overview
  • 4.2. St. Jude Medical, Inc.
    • 4.2.1. Company Overview
  • 4.3. Boston Scientific Corporation
    • 4.3.1. Company Overview
  • 4.4. Biotronik SE & Co. KG
    • 4.4.1. Company Overview
  • 4.5. Sorin S.p.A.
    • 4.5.1. Company Overview

5. Cardiac Rhythm Management Market Pipeline Products

6. Financial Deals Landscape

  • 6.1. Acquisition
    • 6.1.1. Merit Medical Completes Acquisition Of Thomas Medical From GE Healthcare For Up To US$167 Million
  • 6.2. Debt Offerings
    • 6.2.1. Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million
    • 6.2.2. Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million
    • 6.2.3. Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million
    • 6.2.4. Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million
    • 6.2.5. Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion
    • 6.2.6. Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million
    • 6.2.7. Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion
  • 6.3. Equity Offerings
    • 6.3.1. Stereotaxis Files Registration Statement For Public Offering Of Securities For Up To US$75 Million
    • 6.3.2. Stereotaxis Completes Rights Offering Of Shares For US$10.2 Million
  • 6.4. Partnerships
    • 6.4.1. ZOLL Medical Enters Into Licensing Agreement With Inovise Medical
  • 6.5. Venture Financing
    • 6.5.1. Rijuven Raises US$0.3 Million In Venture Financing
    • 6.5.2. iRhythm Technologies Raises US$16 Million In Series D Financing
    • 6.5.3. iRhythm Technologies Raises US$3.5 Million In Venture Financing

7. Recent Developments

  • 7.1. Corporate Communications
    • 7.1.1. Apr 16, 2014: Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network
    • 7.1.2. Apr 08, 2014: Ventripoint Corporate Update and Resignation of Director
    • 7.1.3. Feb 18, 2014: SurModics Announces Changes to Board of Directors
    • 7.1.4. Feb 14, 2014: Stereotaxis Appoints William C. Mills III to Chief Executive Officer
    • 7.1.5. Jan 06, 2014: Catalyst Pharmaceutical Partners Reports Successful Completion of Type B Breakthrough Therapy Meeting With FDA on Firdapse Tablets Development Program
    • 7.1.6. Dec 05, 2013: Anxious Patient Group Calls on NICE to Approve Only Drug Treatment for Ultra-Rare Disease
    • 7.1.7. Nov 04, 2013: Canbex Therapeutics Commences Phase I Clinical Trial of Lead Product VSN16R as a Potential Treatment for Spasticity in Multiple Sclerosis
    • 7.1.8. Sep 25, 2013: Accellent Announces the Promotion of Jeremy Friedman to President and Chief Operating Officer for the Cardio & Vascular Business and the Appointment of Richard Johnson as Interim CFO
    • 7.1.9. Sep 20, 2013: SurModics Announces Board Changes
    • 7.1.10. Sep 16, 2013: Arena Pharmaceuticals Provides Update as Eisai's Launch of BELVIQ CIV Enters Consumer Phase
    • 7.1.11. Aug 19, 2013: Orthofix Receives Expected NASDAQ Notice Related to Late Filing of Form 10-Q
    • 7.1.12. Aug 16, 2013: Stereotaxis Announces Listing Transfer to NASDAQ Capital Market
    • 7.1.13. Aug 02, 2013: China CDC Enters Into R&D Agreement With Aeras Global For TB Vaccine
    • 7.1.14. Jul 23, 2013: Dean Schauer, Executive Vice President, Cardio & Vascular Group, Announces Resignation
    • 7.1.15. Jul 02, 2013: InSite Vision Receives Notice of Allowance from USPTO for Patent on DuraSite 2 Ophthalmic Drug Delivery System
  • 7.2. Financial Announcements
    • 7.2.1. May 06, 2014: Stereotaxis Reports 2014 First Quarter Financial Results
    • 7.2.2. May 01, 2014: SurModics Reports Second Quarter Fiscal 2014 Results
    • 7.2.3. Apr 22, 2014: Bard Announces First Quarter Results
    • 7.2.4. Feb 25, 2014: Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results
    • 7.2.5. Feb 18, 2014: Medtronic Reports Third Quarter Earnings
    • 7.2.6. Jan 30, 2014: Bard Announces Fourth Quarter Results
    • 7.2.7. Jan 30, 2014: SurModics Reports First Quarter Fiscal 2014 Results
    • 7.2.8. Dec 11, 2013: Bard Declares Quarterly Dividend
    • 7.2.9. Nov 19, 2013: Medtronic Reports Second Quarter Earnings
    • 7.2.10. Nov 14, 2013: Stereotaxis Reports Third Quarter 2013 Financial Results
    • 7.2.11. Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014
    • 7.2.12. Nov 07, 2013: Accellent Announces Third Quarter 2013 Results
    • 7.2.13. Nov 05, 2013: SurModics Reports Fourth Quarter and Full Year 2013 Results
    • 7.2.14. Oct 29, 2013: SurModics to Webcast Fourth Quarter and Fiscal Year 2013 Earnings Conference Call on November 5
    • 7.2.15. Oct 23, 2013: Stereotaxis Announces Preliminary Third Quarter 2013 Financial Results in Preparation for Rights Offering
    • 7.2.16. Oct 22, 2013: Bard Announces Third Quarter Results
    • 7.2.17. Oct 09, 2013: Bard Declares Quarterly Dividend
    • 7.2.18. Oct 01, 2013: Bard to Host Earnings Conference Call on October 22, 2013
    • 7.2.19. Aug 20, 2013: Medtronic Reports First Quarter Earnings
    • 7.2.20. Aug 13, 2013: Accellent Announces Second Quarter 2013 Results
    • 7.2.21. Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014
    • 7.2.22. Aug 08, 2013: Stereotaxis Reports Second Quarter 2013 Financial Results; Announces Capital Transactions
    • 7.2.23. Aug 06, 2013: Accellent Announces Timing of Second Quarter 2013 Earnings Release and Conference Call
    • 7.2.24. Jul 31, 2013: SurModics Reports Third Quarter Fiscal 2013 Results
    • 7.2.25. Jul 24, 2013: Bard Announces Second Quarter Results
    • 7.2.26. Jul 23, 2013: SurModics to Webcast Third Quarter 2013 Earnings Conference Call on July 31
    • 7.2.27. May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013
    • 7.2.28. May 14, 2013: Accellent Reports Revenue Of $120.8m In Q1 2013
    • 7.2.29. May 13, 2013: Stereotaxis Reports Revenue Of $8.4m In Q1 2013
  • 7.3. Government and Public Interest
    • 7.3.1. Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
    • 7.3.2. Jan 06, 2014: Bard to Host Earnings Conference Call on January 30, 2014
    • 7.3.3. Dec 20, 2013: Bard to Present at J.P. Morgan Healthcare Conference
    • 7.3.4. Dec 06, 2013: Stereotaxis to Present at Oppenheimer 24th Annual Healthcare Conference in New York on December 11, 2013
    • 7.3.5. Dec 04, 2013: SurModics to Present at Oppenheimer Healthcare Conference
    • 7.3.6. Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference
    • 7.3.7. Nov 26, 2013: SurModics to Present at Piper Jaffray Healthcare Conference
    • 7.3.8. Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference
    • 7.3.9. Nov 20, 2013: Bard to Present at Piper Jaffray Healthcare Conference
    • 7.3.10. Nov 12, 2013: SurModics to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
    • 7.3.11. Oct 29, 2013: Bard to Present at Credit Suisse Healthcare Conference
    • 7.3.12. Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference
    • 7.3.13. Sep 03, 2013: Bard to Host Conference Call on September 4, 2013
    • 7.3.14. Aug 27, 2013: SurModics to Present at CL King's Best Ideas Conference
    • 7.3.15. Aug 20, 2013: Bard to Present at Morgan Stanley Global Healthcare Conference
    • 7.3.16. May 21, 2013: SurModics to Present at the Jefferies Global Healthcare Conference
  • 7.4. Legal And Regulatory
    • 7.4.1. Apr 11, 2014: Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve
    • 7.4.2. Mar 12, 2014: Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
    • 7.4.3. Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures
    • 7.4.4. Oct 19, 2013: Medtronic Statement on Medical Device Security
    • 7.4.5. Aug 16, 2013: Glancy Binkow & Goldberg Announces Class Action Lawsuit Against Orthofix International
    • 7.4.6. Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records
    • 7.4.7. Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc.
  • 7.5. Other Significant Developments
    • 7.5.1. Apr 16, 2014: Bard Declares Quarterly Dividend
    • 7.5.2. Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014
    • 7.5.3. Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai
    • 7.5.4. Jan 08, 2014: BIOTRONIK Devices and Leads, including latest DX System Technology, Now Available for Veterans Affairs Clients
    • 7.5.5. Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles
    • 7.5.6. Nov 27, 2013: Stereotaxis announces results of rights offering
    • 7.5.7. Sep 03, 2013: SurModics Announces Organizational Changes
    • 7.5.8. Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014
    • 7.5.9. Jul 22, 2013: SurModics to Present at the InvestMNt Conference
  • 7.6. Product News
    • 7.6.1. Feb 13, 2014: New Data Support Use of iRhythm's ZIO Service to Identify Cardiac Arrhythmias in Stroke and TIA Patients
    • 7.6.2. Jan 27, 2014: Laerdal Medical and Wolters Kluwer Health Introduce Virtual Simulation Learning Tool for Nursing Students
    • 7.6.3. Jan 02, 2014: ZIO Service Identifies Significantly More Cardiac Arrhythmias Than the Traditional Holter Monitor, According to Study Published Online in the American Journal of Medicine
    • 7.6.4. Dec 20, 2013: First-in-Man Implantation of CARMAT's Bioprosthetic Artificial Heart
    • 7.6.5. Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall
    • 7.6.6. Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation
    • 7.6.7. Jun 25, 2013: nContact Continues To Expand Intellectual Property Portfolio For Its Multidisciplinary Approach For Treatment Of Cardiac Arrhythmias
  • 7.7. Strategy And Business Planning
    • 7.7.1. Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland
    • 7.7.2. Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies
    • 7.7.3. Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation

8. Appendix

  • 8.1. Research Methodology
    • 8.1.1. Coverage
    • 8.1.2. Secondary Research
    • 8.1.3. Primary Research
    • 8.1.4. Market Modeling and Forecasting
    • 8.1.5. Company Share Analysis
    • 8.1.6. Distribution Share Analysis
  • 8.2. Expert Panel
  • 8.3. GlobalData Consulting
  • 8.4. Contact Us
  • 8.5. Disclaimer

List of Tables

  • Table 1: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Table 2: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Table 3: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Table 4: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Table 5: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Table 6: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Table 7: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Table 8: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Table 9: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012
  • Table 10: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020
  • Table 11: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012
  • Table 12: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012
  • Table 13: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012
  • Table 14: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020
  • Table 15: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020
  • Table 16: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020
  • Table 17: Cardiac Rhythm Management Market, United States, Average Price ($), Historic, 2005-2012
  • Table 18: Cardiac Rhythm Management Market, United States, Average Price ($), Forecast, 2012-2020
  • Table 19: Cardiac Rhythm Management Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012
  • Table 20: Cardiac Rhythm Management Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012
  • Table 21: Cardiac Rhythm Management Market Pipeline Products
  • Table 22: Merit Medical Completes Acquisition Of Thomas Medical From GE Healthcare For Up To US$167 Million
  • Table 23: Medtronic Completes Public Offering Of Notes Due 2017 For US$250 Million
  • Table 24: Medtronic Completes Public Offering Of 0.875% Notes Due 2017 For US$250 Million
  • Table 25: Medtronic Completes Public Offering Of Notes Due 2024 For US$850 Million
  • Table 26: Medtronic Completes Public Offering Of Notes Due 2044 For US$650 Million
  • Table 27: Medtronic Completes Public Offering Of Notes Due 2018 For US$1 Billion
  • Table 28: Medtronic Completes Public Offering Of Notes Due 2043 For US$750 Million
  • Table 29: Medtronic Completes Public Offering Of Notes Due 2023 For US$1.25 Billion
  • Table 30: Stereotaxis Files Registration Statement For Public Offering Of Securities For Up To US$75 Million
  • Table 31: Stereotaxis Completes Rights Offering Of Shares For US$10.2 Million
  • Table 32: ZOLL Medical Enters Into Licensing Agreement With Inovise Medical
  • Table 33: Rijuven Raises US$0.3 Million In Venture Financing
  • Table 34: iRhythm Technologies Raises US$16 Million In Series D Financing
  • Table 35: iRhythm Technologies Raises US$3.5 Million In Venture Financing
  • Table 36 Total Number of Primary Research Participants, Cardiovascular Devices Market, by Country

List of Figures

  • Figure 1: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Figure 2: Cardiac Rhythm Management Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Figure 3: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Figure 4: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Figure 5: Pacemakers Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012
  • Figure 6: Cardiac Resynchronisation Therapy Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Figure 7: Implantable Cardioverter Defibrillators Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Figure 8: Pacemakers Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020
  • Figure 9: Cardiac Rhythm Management Market, United States, Volume (Units), Historic, 2005-2012
  • Figure 10: Cardiac Rhythm Management Market, United States, Volume (Units), Forecast, 2012-2020
  • Figure 11: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Historic, 2005-2012
  • Figure 12: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Historic, 2005-2012
  • Figure 13: Pacemakers Market, United States, Volume (Units), Historic, 2005-2012
  • Figure 14: Cardiac Resynchronisation Therapy Market, United States, Volume (Units), Forecast, 2012-2020
  • Figure 15: Implantable Cardioverter Defibrillators Market, United States, Volume (Units), Forecast, 2012-2020
  • Figure 16: Pacemakers Market, United States, Volume (Units), Forecast, 2012-2020
  • Figure 17: Cardiac Rhythm Management Market, United States, Company Share (%), 2012
  • Figure 18: GlobalData Epidemiology-Based Forecasting Model
  • Figure 19: GlobalData Capital Equipment-Based Forecasting Model
  • Figure 20: Primary Interviews by Participant Type (%)
Back to Top